晚期胃癌联合辅助化疗用药方案分析

Analysis of the Regimen of Combined Adjuvant Chemotherapy for Advanced Gastric Cancer

目的探讨晚期胃癌联合辅助化疗用药的合理方案选择。方法收集我院确诊为晚期胃癌的患者作为研究对象,将其随机分为研究组(接受多西他赛、奥沙利铂和替吉奥化疗方案)和对照组(接受伊立替康、L-OHP和替吉奥方案)。对比两组晚期胃癌化疗疗效;两组辅助化疗后手术切除情况;两组用药期间不良反应。结果研究组和对照组晚期胃癌化疗疗效分别为54.29%、34.29%,组间比较,差异具有统计学意义(P<0.05);研究组和对照组辅助化疗后手术切除情况比较,差异具有统计学意义(P<0.05)。两组用药期间不良反应比较,差异不具有统计学意义(P>0.05)。结论多西他赛、奥沙利铂和替吉奥化疗方案临床有效率高,可有效杀灭肿瘤细胞,不良反应较轻,可作为晚期胃癌一线选择方案。

Objective To explore the rational choice of combined adjuvant chemotherapy for advanced gastric cancer. Methods The patients diagnosed as advanced gastric cancer in our hospital were selected as the research objects and they were randomly divided into study group （docetaxel, oxaliplatin and S-1 chemotherapy） and control group （receiving irinotecan, L-OHP and S-1）. Comparison of two groups of advanced gastric cancer chemotherapy effect, two groups of adjuvant chemotherapy after surgical excision, two groups of adverse reactions during the drug use. Results The chemotherapy effcacy of the advanced gastric cancer in the study group and the control group was 54.29% and 34.29% respectively, the difference was statistically signifcant （P〈0.05）. There was a difference in the surgical resection between the study group and the control group after adjuvant chemotherapy, the difference was statistically significant （P〈0.05）. There was no difference in the adverse reaction between two groups （P〉0.05）. Conclusion Docetaxel, oxaliplatin and S-1 chemotherapy clinical effective rate is high, can effectively kill tumor cells, with mild adverse reactions, can be used as a frst-line option for advanced gastric cancer.